3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
481
Neoplasms
294
Breast Neoplasms
282
Colorectal Neoplasms
225
Neoplasm Metastasis
191
Prostatic Neoplasms
172
Ovarian Neoplasms
165
Lung Neoplasms
155
Multiple Myeloma
153
Recurrence
133
Melanoma
117
Pancreatic Neoplasms
114
Squamous Cell Carcinoma of Head and Neck
105
Stomach Neoplasms
98
Endometrial Neoplasms
98
Leukemia, Myeloid, Acute
96
Small Cell Lung Carcinoma
85
Leukemia, Lymphocytic, Chronic, B-Cell
83
Lymphoma, Non-Hodgkin
82
Triple Negative Breast Neoplasms
81
Carcinoma, Renal Cell
81
Carcinoma, Hepatocellular
80
Urinary Bladder Neoplasms
75
Lymphoma, Large B-Cell, Diffuse
73
Lymphoma, Follicular
67
Advanced Solid Tumors
64
Lymphoma
62
Glioblastoma
60
Parkinson Disease 4, Autosomal Dominant Lewy Body
56
Head and Neck Neoplasms
54
Interventions
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fatty Liver
×
90 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled